Enhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
Living RheumEnhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
APOL1 and Chronic Kidney Disease: New Findings in African Populations
Clinician's RoundtableAPOL1 and Chronic Kidney Disease: New Findings in African Populations
Diagnosing IgAN: The Importance of Early and Accurate Identification
Clinician's RoundtableDiagnosing IgAN: The Importance of Early and Accurate Identification
Investigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
Clinician's RoundtableInvestigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
Achieving Optimal Outcomes in Lupus Nephritis: Key Updates from the 2024 ACR Guidelines
AudioAbstractsAchieving Optimal Outcomes in Lupus Nephritis: Key Updates from the 2024 ACR Guidelines
IgAN Explained: Key Differences from Other Kidney Conditions
Clinician's RoundtableIgAN Explained: Key Differences from Other Kidney Conditions
Upgrade Your Adult Patients’ IgAN Treatment
Medical Industry FeatureUpgrade Your Adult Patients’ IgAN Treatment
IgAN Insights: The Potential Role of the Complement System in Disease Progression
Medical Industry FeatureIgAN Insights: The Potential Role of the Complement System in Disease Progression
Identifying Patients at High-Risk for IgAN Progression: Key Factors to Know
Medical Industry FeatureIdentifying Patients at High-Risk for IgAN Progression: Key Factors to Know
The Pathogenesis of Complement 3 Glomerulopathy (C3G)
Medical Industry FeatureThe Pathogenesis of Complement 3 Glomerulopathy (C3G)
The Endothelin System and IgAN: Emerging Evidence
Medical Industry FeatureThe Endothelin System and IgAN: Emerging Evidence
IgAN Insights: The Impact of Proteinuria
Medical Industry FeatureIgAN Insights: The Impact of Proteinuria
- 03/25/2025
- 03/24/2025
- 03/24/2025
- 03/20/2025
- 03/19/2025
- 03/18/2025